Results 1 to 10 of about 49,135 (301)

Pharmacokinetics and Pharmacogenetics of Dabigatran

Рациональная фармакотерапия в кардиологии, 2021
Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists.
A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder   +4 more
doaj   +2 more sources

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. [PDF]

New England Journal of Medicine, 2017
BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be ...
Bernstein, Richard A., Dubiel, Robert, Eikelboom, John W., Glund, Stephan, Huisman, Menno V., Hylek, Elaine M., Kam, Chak-Wah, Kamphuisen, Pieter W., Kreuzer, Jörg, Levy, Jerrold H., Pollack, Charles V., Reilly, Paul A., Royle, Gordon, Sellke, Frank W., Stangier, Joachim, Steiner, Thorsten, van Ryn, Joanne, Verhamme, Peter, Wang, Bushi, Weitz, Jeffrey I., Young, Laura   +20 more
core   +4 more sources

Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran [PDF]

, 2015
© Otsui et al. 2015BACKGROUND: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required; however, a
Gorog, Diana A, Inoue, Nobutaka, Iwata, Sachiyo, Otsui, Kazunori, Ozawa, Toru, Suzuki, Atsushi, Takei, Asumi, Yamamoto, Junichiro, Yoshioka, Takayuki   +8 more
core   +4 more sources

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran [PDF]

Scientific Reports
Dabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than ...
Jong-Min Kim, Young Yoon Bang, Kyoung-Ah Kim, Jin-Woo Park, Ji-Young Park   +4 more
doaj   +2 more sources

Idarucizumab for Dabigatran Reversal

New England Journal of Medicine, 2015
Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of ...
Pollack Jr, C.V., Reilly, P.A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R.A., Dubiel, R., Huisman, M.V., Hylek, E.M., Kamphuisen, P.W., Kreuzer, J., Levy, J.H., Sellke, F.W., Stangier, J., Steiner, T., Wang, B., Kam, C.W., Weitz, J.I.   +17 more
openaire   +4 more sources

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Frontiers in Medicine, 2020
Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Laurent Bertoletti, Nadine Ajzenberg, Nadine Ajzenberg, Pascale Gaussem, Pascale Gaussem, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Pierre-Marie Roy, Agnès Lillo-le Louët, Agnès Lillo-le Louët, David M. Smadja, David M. Smadja, David M. Smadja   +39 more
doaj   +2 more sources

Dabigatran [PDF]

American Journal of Neuroradiology, 2011
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
L, Murphy, L, Lawler, E C, Kavanagh
  +6 more sources

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation [PDF]

New England Journal of Medicine, 2017
Hugh Calkins, Stephan Willems, Edward P. Gerstenfeld, Atul Kumar, Richard J. Schilling, Stefan H. Hohnloser, Ken Okumura, Harvey Serota, Matias Nordaby, Kelly Guiver, Branislav Biss, Marc A. Brouwer, Massimo Grimaldi   +12 more
semanticscholar   +3 more sources

Dabigatran Etexilate Induces Cytotoxicity in Rat Gastric Epithelial Cell Line via Mitochondrial Reactive Oxygen Species Production

Cells, 2021
Dabigatran is a novel oral anticoagulant that directly inhibits free and fibrin-bound thrombins and exerts rapid and predictable anticoagulant effects. While the use of this reagent has been associated with an increased risk of gastrointestinal bleeding,
Hiromi Kurokawa, Atsushi Taninaka, Hidemi Shigekawa, Hirofumi Matsui   +3 more
doaj   +1 more source

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects

Pharmaceuticals, 2023
Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of
Hyewon Chung, Jong-Min Kim, Jin-Woo Park, Jihyeon Noh, Kyoung-Ah Kim, Ji-Young Park   +5 more
doaj   +1 more source